tigit inhibitors pipeline insight

DelveInsight’s, “TIGIT Inhibitors - Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in TIGIT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TIGIT Inhibitors Understanding

TIGIT Inhibitors: Overview

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistally, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIGIT Inhibitors R&D. The therapies under development are focused on novel approaches for TIGIT Inhibitors.

TIGIT Inhibitors Emerging Drugs Chapters

This segment of the TIGIT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

TIGIT Inhibitors Emerging Drugs

 

Tiragolumab: Genentech

Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body’s immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell antitumor activity.

 

Ociperlimab: BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, resulting in activation of T cell mediated antitumor immune responses.

Further product details are provided in the report……..

TIGIT Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TIGIT Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on TIGIT Inhibitors

There are approx. 14+ key companies which are developing the TIGIT Inhibitors. The companies which have their TIGIT Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Genentech.

Phases

DelveInsight’s report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

TIGIT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIGIT Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIGIT Inhibitors therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIGIT Inhibitors drugs.

TIGIT Inhibitors Report Insights

• TIGIT Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TIGIT Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing TIGIT Inhibitors drugs?
• How many TIGIT Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIGIT Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIGIT Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TIGIT Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?